Leap Therapeutics, Inc. (NASDAQ:LPTX) Expected to Announce Earnings of -$0.11 Per Share

Equities analysts predict that Leap Therapeutics, Inc. (NASDAQ:LPTXGet Rating) will post ($0.11) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Leap Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Leap Therapeutics posted earnings per share of ($0.12) in the same quarter last year, which suggests a positive year over year growth rate of 8.3%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Leap Therapeutics will report full-year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts expect that the company will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.61) to ($0.39). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Leap Therapeutics.

Leap Therapeutics (NASDAQ:LPTXGet Rating) last issued its quarterly earnings data on Friday, March 11th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. Leap Therapeutics had a negative net margin of 2,705.80% and a negative return on equity of 55.42%.

Separately, Zacks Investment Research raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Thursday, March 17th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $4.00.

Shares of NASDAQ:LPTX opened at $1.59 on Friday. The firm has a 50 day moving average of $1.88 and a 200-day moving average of $2.42. The stock has a market capitalization of $140.43 million, a PE ratio of -3.31 and a beta of 0.56. Leap Therapeutics has a 12 month low of $1.33 and a 12 month high of $4.17.

Several institutional investors have recently bought and sold shares of LPTX. FMR LLC increased its position in Leap Therapeutics by 63.3% during the 1st quarter. FMR LLC now owns 1,563,124 shares of the company’s stock valued at $2,923,000 after purchasing an additional 606,000 shares during the period. Morgan Stanley increased its position in Leap Therapeutics by 426,666.7% during the 1st quarter. Morgan Stanley now owns 38,409 shares of the company’s stock valued at $73,000 after purchasing an additional 38,400 shares during the period. Citadel Advisors LLC acquired a new stake in Leap Therapeutics during the 2nd quarter valued at approximately $53,000. International Assets Investment Management LLC acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $40,000. Finally, Valeo Financial Advisors LLC acquired a new stake in Leap Therapeutics during the 3rd quarter valued at approximately $52,000. 61.55% of the stock is currently owned by institutional investors.

About Leap Therapeutics (Get Rating)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

See Also

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.